标题
Cardiovascular effects of gliptins
作者
关键词
-
出版物
Nature Reviews Cardiology
Volume 10, Issue 2, Pages 73-84
出版商
Springer Nature
发表日期
2013-01-08
DOI
10.1038/nrcardio.2012.183
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Steven G. Chrysant et al. AMERICAN JOURNAL OF CARDIOLOGY
- Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
- (2012) Chun-Yao Huang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
- (2012) Robert Klempfner et al. Cardiovascular Diabetology
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Incretin-based therapies and cardiovascular risk
- (2012) Edoardo Mannucci et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
- (2012) Dhanwantee Mundil et al. Diabetes & Vascular Disease Research
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients
- (2012) Shlomit Koren et al. Diabetes Technology & Therapeutics
- Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
- (2012) B. Eliasson et al. DIABETOLOGIA
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Saxagliptin
- (2012) Lily P.H. Yang DRUGS
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Cardioprotective Effects of Metformin and Vildagliptin in Adult Rats with Insulin Resistance Induced by a High-Fat Diet
- (2012) Nattayaporn Apaijai et al. ENDOCRINOLOGY
- The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice
- (2012) Min Shen et al. Experimental Diabetes Research
- Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism
- (2012) Limei Liu et al. HYPERTENSION
- Sitagliptin Exerts an Antinflammatory Action
- (2012) Antoine Makdissi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction
- (2012) Simone Post et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Dipeptidyl Peptidase-4 Inhibitor
- (2012) Toyoaki Murohara JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
- (2012) Nancy J. Brown Journal of the American Society of Hypertension
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
- (2012) Ashish Kumar Gupta et al. PLATELETS
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- (2011) Benjamin M. Scirica et al. AMERICAN HEART JOURNAL
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus
- (2011) Vivian A. Fonseca AMERICAN JOURNAL OF CARDIOLOGY
- The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
- (2011) Yumei Ye et al. BASIC RESEARCH IN CARDIOLOGY
- Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
- (2011) Sameer Ansar et al. Cardiovascular Diabetology
- Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
- (2011) Meimei Yin et al. Cardiovascular Diabetology
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
- (2011) Fernando Ovalle CLINICAL THERAPEUTICS
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
- (2011) Sarah Farr et al. CURRENT OPINION IN LIPIDOLOGY
- The role of incretins in salt-sensitive hypertension
- (2011) Tetsuhiro Tanaka et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes
- (2011) A. Chaudhuri et al. DIABETES OBESITY & METABOLISM
- Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
- (2011) A. J. Tremblay et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and HbA1c target of
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence
- (2011) R. E. van Genugten et al. DIABETES OBESITY & METABOLISM
- Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
- (2011) Matteo Monami et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
- (2011) Nelson Gomez et al. EUROPEAN JOURNAL OF HEART FAILURE
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
- (2011) Nga N Ta et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effects of DPP-4 inhibition on cardiac metabolism and function in mice
- (2011) M. Lenski et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
- (2010) Yumei Ye et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
- (2010) Barbara Huisamen et al. CARDIOVASCULAR DRUGS AND THERAPY
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Sitagliptin
- (2010) Sohita Dhillon DRUGS
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
- (2010) Edwin K. Jackson HYPERTENSION
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats
- (2010) Bruna PM Pacheco et al. JOURNAL OF HYPERTENSION
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
- (2010) Liliana Ferreira et al. MEDIATORS OF INFLAMMATION
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- SDF-1α as a therapeutic stem cell homing factor in myocardial infarction
- (2010) Santhosh K. Ghadge et al. PHARMACOLOGY & THERAPEUTICS
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
- (2010) Jitendra Vaghasiya et al. REGULATORY PEPTIDES
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
- (2009) Marc Vanderheyden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay
- (2009) Kevin Niswender DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Diabetes medications and body weight
- (2009) Joanna Mitri et al. Expert Opinion On Drug Safety
- Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
- (2009) Manfredi Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
- (2009) Kiwon Ban et al. Journal of the American Society of Hypertension
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
- (2008) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Hypoglycaemia in Type 2 diabetes
- (2008) S. A. Amiel et al. DIABETIC MEDICINE
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessing the Cardiovascular Safety of Diabetes Therapies
- (2008) Allison B. Goldfine NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search